probucol (lorelco) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Probucol is used to lower levels of cholesterol (a fat-like substance) in the blood. Probucol is a drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. This may help prevent medical problems caused by cholesterol clogging the blood vessels. Probucol was voluntarily removed from the market in the United States during 1995. The withdrawal from the market was due to safety concern. robucol lowers serum cholesterol by increasing the fractional rate of low-density lipoprotein (LDL) catabolism in the final metabolic pathway for cholesterol elimination from the body. Additionally, probucol may inhibit early stages of cholesterol biosynthesis and slightly inhibit dietary cholesterol absorption. Recent information suggests that probucol may inhibit the oxidation and tissue deposition of LDL cholesterol, thereby inhibiting atherogenesis. It appears to inhibits ABCA1-mediated cellular lipid efflux.   NCATS

Chemistry

  • SMILES: CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC2=CC(=C(O)C(=C2)C(C)(C)C)C(C)(C)C
  • InChIKey: FYPMFJGVHOHGLL-UHFFFAOYSA-N
  • Mol. Mass: 516.842
  • ALogP: 9.91
  • ChEMBL Molecule:
    probucol  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

4,4'- (isopropylidenedithio)bis(2,6-di-tert-butylphenol) | acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole | biphenabid | bisbid | bisphenabid | dh-581 | lesterol | lorelco | lurselle | phenbutol | probucol | probucolum | serterol | sinlestal | superlipid

Organizations (16)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (1)


 

Hypercholesterolemia (approved 1977)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Alzheimer Disease (Phase 2)

Arteriosclerosis Obliterans (Phase 4)

Atherosclerosis (Phase 4)

Brain Ischemia (Phase 4)

Cognition Disorders (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 4)

Glomerulonephritis (Phase 4)

Glomerulonephritis, IGA (Phase 4)

Healthy Volunteers (Phase 4)

Hypercholesterolemia (Phase 4)

Hyperlipidemias (Phase 4)

Intracranial Arteriosclerosis (Phase 4)

Intracranial Hemorrhages (Phase 4)

Ischemic Stroke (Phase 4)

Kidney Diseases (Phase 4)

Peripheral Arterial Disease (Phase 2)

Therapeutics (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue